Skip to main content
Top
Published in: Breast Cancer Research 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer

Authors: Yi Fang Lee, Lance David Miller, Xiu Bin Chan, Michael A. Black, Brendan Pang, Chee Wee Ong, Manuel Salto-Tellez, Edison T. Liu, Kartiki V. Desai

Published in: Breast Cancer Research | Issue 1/2017

Login to get access

Excerpt

Main text: After the publication of this work [1] an error was noticed in Fig. 8. In the SMAD2P465/467 panel, the images for MCF-7 and MDA MB 231 cells were accidentally duplicated. The corrected figure is shown below. We apologize for this error, which does not affect the findings or conclusions of the article.
Literature
1.
go back to reference Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast cancer research: BCR. 2012;14(3):R85.CrossRefPubMedPubMedCentral Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast cancer research: BCR. 2012;14(3):R85.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer
Authors
Yi Fang Lee
Lance David Miller
Xiu Bin Chan
Michael A. Black
Brendan Pang
Chee Wee Ong
Manuel Salto-Tellez
Edison T. Liu
Kartiki V. Desai
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2017
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-017-0830-9

Other articles of this Issue 1/2017

Breast Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine